Get started
Author

Yasir M. Nagarwala

Observed names: Y Nagarwala, Y. M. Nagarwala, Y. Nagarwala, Yasir M Nagarwala, Yasir Nagarwala
Observed institutions: Sarah Cannon Research Institute, GlaxoSmithKline (United Kingdom), Yonsei University, Georgetown University Medical Center, Queen Elizabeth II Health Sciences Centre, Jewish General Hospital, Mackay Memorial Hospital, Virginia Oncology Associates, Menarini Group (Luxembourg), Menarini Group (Italy), GlaxoSmithKline (United States), Dana-Farber Cancer Institute, Florida Cancer Specialists & Research Institute, Virginia Cancer Specialists, Tennessee Oncology, Instituto Nacional de Cancerología, Oncology Hematology Care, Georgia Cancer Specialists, Menarini Group (Germany), Celgene (United States), Yonsei Cancer Hospital, McGill University
OpenAlex ID: A5003279484
Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919.
2012 · Karen A. Gelmon, Frances Boyle, et al. · Journal of Clinical Oncology · 68
Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling
2013 · Frankie Ann Holmes, Virginia Espina, et al. · BMC Research Notes · 67
PDF
Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors
2010 · Matthew D. Galsky, Daniel D. Von Hoff, et al. · Investigational New Drugs · 67
Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapy.
2011 · F. A. Holmes, Y. M. Nagarwala, et al. · Journal of Clinical Oncology · 48
Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma
2014 · M A Dimopoulos, A S Swern, et al. · Blood Cancer Journal · 44
PDF
Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma
2015 · Steven R. Arikian, Dejan Milentijevic, et al. · Current Medical Research and Opinion · 37
PDF
Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen
2012 · Denise A. Yardley, Lowell Hart, et al. · Breast Cancer Research and Treatment · 36
PDF
Connect MM Registry: The Importance of Establishing Baseline Disease Characteristics
2014 · Robert M. Rifkin, Rafat Abonour, et al. · Clinical Lymphoma Myeloma & Leukemia · 34
Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919.
2012 · Karen A. Gelmon, Frances Boyle, et al. · Journal of Clinical Oncology · 34
Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma
2015 · S. Z. Usmani, J. D. Cavenagh, et al. · Journal of Medical Economics · 28
PDF
Connect MM® – the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide
2016 · Robert M. Rifkin, Rafat Abonour, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 24
PDF
A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer
2016 · Melissa J. LaBonte, Dongyun Yang, et al. · Molecular Cancer Therapeutics · 10
A global, multicenter phase II trial of lapatinib plus capecitabine in gastric cancer.
2011 · M. Pishvaian, D. Sakaeva, et al. · Journal of Clinical Oncology · 10
Optimizing capillary leak syndrome prevention and management in patients receiving tagraxofusp for blastic plasmacytoid dendritic cell neoplasm
2025 · Andrew A. Lane, Cristina Papayannidis, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 3
PDF
Abstract P3-10-08: Elacestrant real-world progression-free survival (rwPFS) of adult patients with ER+/HER2-, advanced breast cancer: a retrospective analysis using insurance claims in the United States
2025 · Elyse Swallow, Jessica Maitland, et al. · Clinical Cancer Research · 3
Cost-Effectiveness Of Lenalidomide and Bortezomib In Patients With Previously Untreated Multiple Myeloma (MM)
2013 · Gerry Oster, Ariel Berger, et al. · Blood · 3
Connect MM®—the Multiple Myeloma (MM) Disease Registry: Interim Analysis of Overall Survival and Outcomes in Patients with High-Risk Disease
2014 · Jatin J. Shah, Rafat Abonour, et al. · Blood · 2
Cost of Treatment for Relapsed/Refractory Multiple Myeloma.
2015 · Safiya Abouzaid, Craig Gibson, et al. · PubMed Central · 1
Lenalidomide Dose Modifications and Associated Patient Outcomes in Newly Diagnosed Multiple Myeloma (NDMM)
2015 · S. Usmani, G. Binder, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Characteristics and survival of African American (AA) newly diagnosed multiple myeloma (NDMM) patients (Pts): A report from the Connect MM Registry.
2015 · Kathleen Toomey, Cristina Gasparetto, et al. · Journal of Clinical Oncology · 1
Connect MM®—the Multiple Myeloma (MM) Disease Registry: Incidence of Second Primary Malignancies (SPM)
2014 · Robert M. Rifkin, Rafat Abonour, et al. · Blood · 1
Continuous lenalidomide (LEN) therapy versus observation following nonimmunomodulatory compound-based induction therapy in newly diagnosed multiple myeloma (NDMM): MM-027 trial.
2014 · Saad Zafar Usmani, Yasir M. Nagarwala, et al. · Journal of Clinical Oncology · 1
Abstract OT1-1-07: Human epidermal growth factor receptor 2 (HER2) suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (LTP112515)
2012 · N Lin, MA Danso, et al. · Cancer Research · 1
Lapatinib and trastuzumab: Molecular effects and efficacy, separately and combined in breast cancer.
2010 · F. A. Holmes, V. A. Espina, et al. · Journal of Clinical Oncology · 1
Supplementary Figure Legends from A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer
2023 · Melissa J. LaBonte, Dongyun Yang, et al.
Works count: 56
Citation count: 525
H-index: 11
I10-index: 13
Year
Topic
Type